Introduction <p>Hypomagnesemia is a well-known side effect of certain chemotherapy drugs, especially platinum-based agents. Renal magnesium wasting is more frequent and better described with cisplatin. Carboplatin induced hypomagnesemia is common, generally mild, occurs during the treatment or shortly thereafter, and typically stabilizes or normalizes during follow up.</p> Case presentation <p>We report the case of a 58-year-old female patient with metastatic breast cancer, who presented for generalized pain and palpitations. Laboratory evaluation revealed severe hypomagnesemia due to renal magnesium wasting, one year after cessation of carboplatin therapy. A review of her other medications and other potential causes of hypomagnesemia did not identify additional contributors to magnesium wasting. Magnesium levels were normal before carboplatin initiation.</p> Conclusion <p>This case highlights that renal magnesium wasting associated with carboplatin may rarely cause late profound hypomagnesemia, up to one year after treatment discontinuation. Therefore, magnesium levels need to be rigorously followed over long periods of time following carboplatin treatment even after initial reassuring levels.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Case report: delayed profound hypomagnesemia from carboplatin- associated renal magnesium wasting

  • Louaa Chebbo,
  • Elias Karam,
  • Gaelle Salame

摘要

Introduction

Hypomagnesemia is a well-known side effect of certain chemotherapy drugs, especially platinum-based agents. Renal magnesium wasting is more frequent and better described with cisplatin. Carboplatin induced hypomagnesemia is common, generally mild, occurs during the treatment or shortly thereafter, and typically stabilizes or normalizes during follow up.

Case presentation

We report the case of a 58-year-old female patient with metastatic breast cancer, who presented for generalized pain and palpitations. Laboratory evaluation revealed severe hypomagnesemia due to renal magnesium wasting, one year after cessation of carboplatin therapy. A review of her other medications and other potential causes of hypomagnesemia did not identify additional contributors to magnesium wasting. Magnesium levels were normal before carboplatin initiation.

Conclusion

This case highlights that renal magnesium wasting associated with carboplatin may rarely cause late profound hypomagnesemia, up to one year after treatment discontinuation. Therefore, magnesium levels need to be rigorously followed over long periods of time following carboplatin treatment even after initial reassuring levels.